Trialbee Partners With LiveRamp
Trialbee has announced a partnership with LiveRamp, to expand the pool of potential patients and then match and engage patients for clinical trials in a privacy-centric way. Trialbee will leverage LiveRamp’s identity infrastructure and integration network to identify and reach potential clinical trial patients and remain engaged with those patients throughout their clinical trial journey.
Over 80% of regulated phase II-III clinical trials fail to meet planned enrollment targets and are delayed six or more months, jeopardizing data quality and development timelines. Inefficient and untargeted recruitment efforts for late-stage trials cause rise in direct operational development costs and lost revenues due to delayed time to market.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
